One promising approach involves the development of innovative nanoplatforms, such as macrophage–cancer hybrid membranes, which can specifically target GBM malignant cells and effectively silence HIF-1α under hypoxic conditions [190]. This evidence concerns the gene HIF1A and glioblastoma.